Bai J, Zhang Y H, Shao Z H
Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Zhonghua Yi Xue Za Zhi. 2023 Dec 5;103(45):3603-3607. doi: 10.3760/cma.j.cn112137-20231007-00649.
Classical myeloproliferative neoplasms (MPN), also known as PhMPN, includes polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). Secondary myelofibrosis (sMF) and secondary acute myeloid leukemia (sAML) are important disease progressions of MPN. After MPN disease progression, hematopoietic stem cells undergo new clonal evolution, leading to drug resistance, poor treatment effect and poor survival of patients. In recent years, the exploration of the mechanism of disease progression and the precise diagnosis and treatment of MPN have attracted much attention. This article summarizes the research status of MPN disease progression, including the pathogenesis, risk stratification, and precision treatment, in order to provide reference for exploring new diagnosis and treatment methods of MPN disease progression.
经典型骨髓增殖性肿瘤(MPN),也称为PhMPN,包括真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)。继发性骨髓纤维化(sMF)和继发性急性髓系白血病(sAML)是MPN的重要疾病进展。MPN疾病进展后,造血干细胞会经历新的克隆进化,导致耐药性、治疗效果不佳以及患者生存率低。近年来,MPN疾病进展机制的探索以及其精准诊断和治疗备受关注。本文总结了MPN疾病进展的研究现状,包括发病机制、风险分层和精准治疗,以便为探索MPN疾病进展的新诊断和治疗方法提供参考。